View more on these topics

Mark Barnett: Investing in unquoted companies


I am frequently asked about my intentions towards the unquoted companies held within my portfolios. While these look pretty large in absolute terms, in proportionate terms we are talking about some quite small segments of between 4.5 per cent and 6.5 per cent of the portfolio.

I remain of the view holding unquoted stocks in a long-term investment vehicle is the right thing to do. I also believe the optimal way to unearth unquoted investment opportunities is via the relationships we have established over many years with the “tech transfer” or intellectual property commercialisation companies, including IP Group, Imperial Innovations and Allied Minds.

These companies have relationships with a spread of academic institutions, as well as major pharmaceutical companies and the US federal government and, as such, have given us the opportunity to co-invest in new businesses with them.

We embarked upon a process around two years ago to encourage the move of some of the unquoteds, where appropriate, into the quoted sphere.


One such example was Circassia, a biotech company that came from the Imperial Innovations stable. Circassia is an allergy-platform business, which came to the market in March 2014. It was the first float of a biotech company on the London market since 2006 and the largest for over 15 years. The investments we have made over the past few years are now beginning to show the rewards of our patience. Since Circassia, we have also seen Allied Minds, Xeros, Abzena and Puretech Health float on the stock market.

One of our key strengths in the unquoted space comes from our dominant position as major shareholders in these IPC companies. The largest of these is Imperial Innovations, in which my portfolios combined hold a 42 per cent stake. We have 25.4 per cent in IP Group and 34.4 per cent in Allied Minds. We also now hold large stakes in quoted companies Mercia Technologies (29.5 per cent), Puretech Health (32 per cent) and unquoted businesses Cambridge Innovation (20 per cent), Oxford Sciences Innovation (16 per cent) and Eurovestech (30.3 per cent).

These relationships ensure the portfolios are better placed than anyone to benefit from the commercialisation of intellectual property. No one can replicate this position and we typically have the first option to invest in these companies at a relatively early stage in their life cycles. We will also potentially increase stakes over the life cycle, as milestones are met and as their funding needs for commercial development arise.

Not all our unquoted investments will be successful. It is inevitable some companies in the early stages of their development will fail to deliver as hoped. However, the major pricing improvement on float or trade sales that comes from those that do succeed can provide a significant uplift to portfolio performance. More importantly, their long-term future business value can also enhance performance if they are kept within our portfolios. This can prove particularly significant against a backdrop of the more modest capital returns I now expect from large-cap quoted companies.

Mark Barnett is head of UK equities and portfolio manager at Invesco Perpetual 



The Hungerford games: Nutmeg chief searches for ‘killer app’

Nick Hungerford is every inch the 21st Century technology entrepreneur: young, cool, disruptive. In many ways, he is the antithesis of the UK financial services sector. But his journey to founding Nutmeg, the online investment platform attempting to tear strips out of the UK wealth management sector, has its roots firmly planted in the Square […]


Advisers hit out over charge cap claims

Advisers have hit out at suggestions the FCA could intervene on adviser charging by imposing a cap on the cost of advice. Writing in this week’s Money Marketing, Adviser Advocate chief executive Richard Leeson says advisers need to address the discrepancy of percentage-based charging where wealthier clients pay more for the same advice service as […]


Richard Leeson: Uncapped advice fees are under threat

Speaking to an old friend at an IFA practice the other day I opined that uncapped fees were under threat in the long term. My friend agreed and we wondered what could be done about it. You may be asking why uncapped fees are under threat. Let me answer that question by looking at a […]


Martin Lewis: MSE should not be regulated like IFAs founder Martin Lewis says advisers’ client meetings have “massive evidential issues” and claims his website should not be judged alongside the advice industry. In a interview with Money Marketing, to be published in full in our next issue, Lewis hits back at criticism his website is not under close enough scrutiny. He says that, […]

The investment clock

While Trump blazes blond in the political foreground, it’s easy to overlook the economic background to the new political dimension of 2017. Political risk will be a feature of the year: the unpredictable and untested Trump administration has already created uncertainty, which is unlikely to diminish, especially if protectionist rhetoric starts to outweigh promises of […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment